← All Nyxoah SA filings

Nyxoah SA 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
NYXH
Nyxoah SA
20-F: Nyxoah Reports 2025 Financials, FDA Approval Fuels US Commercial Launch
Nyxoah SA achieved FDA approval for its Genio system in August 2025, driving significant revenue growth in 2025, despite continued operating losses and ongoing concerns about its ability to continue as a going concern.
NASDAQ
NYXH
Nyxoah SA
20-F: Nyxoah SA Files 20-F Report: Details Financial Performance and Strategic Initiatives for 2024
Nyxoah SA's 20-F filing reveals the company's financial results for 2024, highlighting its focus on the Genio system and strategic expansion efforts.
NASDAQ
NYXH
Nyxoah SA
20-F: Nyxoah SA Files Form 20-F: Details Financial Performance and Corporate Governance
Nyxoah SA releases its annual report on Form 20-F, providing insights into its financial results, corporate governance, and future strategies.